Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all breast tumors, with a high propensity for metastasis and a poor prognosis. Because TNBC displays a high mutational load compared with other breast cancer types, a neoantigen-based immunotherapy strategy could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Brito Baleeiro, Renato, Liu, Peng, Chard Dunmall, Louisa S, Di Gioia, Carmela, Nagano, Ai, Cutmore, Lauren, Wang, Jun, Chelala, Claude, Nyambura, Lydon Wainaina, Walden, Peter, Lemoine, Nicholas, Wang, Yaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432671/
https://www.ncbi.nlm.nih.gov/pubmed/37586771
http://dx.doi.org/10.1136/jitc-2023-007336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432671/
https://www.ncbi.nlm.nih.gov/pubmed/37586771
http://dx.doi.org/10.1136/jitc-2023-007336

Ejemplares similares